GlobeNewswire·Oct 27, 2026, 4:05 PM ET

Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer

Cardiff Oncology appointed Leila Alland, MD, as interim Chief Medical Officer to succeed Roger Sidhu, MD.
Dr. Alland brings extensive experience leading oncology drug development programs at companies including PMV Pharma, Affimed, Tarveda Therapeutics, AstraZeneca, Bristol Myers Squibb, Novartis, and Schering-Plough.
The company's randomized Phase 2 trial for first-line RAS-mutated metastatic colorectal cancer is ongoing, with median progression-free survival not yet reached in the onvansertib 30 mg plus FOLFIRI and bevacizumab arm.
All patients currently remaining on the trial have been treated for more than 18 months.
Cardiff Oncology plans to initiate its registrational Phase 3 study in the first quarter of 2027.
Dr. Alland holds a medical degree from New York University, a bachelor's degree from the University of Pennsylvania, and completed hematology/oncology training at Memorial Sloan Kettering Cancer Center.
Onvansertib is a specific oral PLK1 inhibitor currently being evaluated for RAS-mutated cancers, with potential applications in other PLK1-driven tumors.